The receptor tyrosine kinase Met and its ligand HGF/SF (hepatocyte growth factor/scatter factor) are essential in the signalling pathways required for embryogenesis and tissue regeneration. Aberrant signalling of this complex is also a feature of many tumours and appears to contribute to the growth, invasiveness and metastasis of both carcinomas and sarcomas. HGF/SF, like many other angiogenic growth factors, employs heparan sulphate as co-receptor. The role of this interaction has not been completely defined but appears to be physiologically relevant. Thus the presence of heparin increases the potency of HGF/SF in experiments with cells in culture leading to elevated downstream signalling effects and, although not vital for the Met-HGF/SF interaction, heparin or heparan sulphate is essential for the activity of certain isoforms of HGF/SF, such as NK1 and NK2. Here, we summarize the progress made in understanding the interaction between heparin and heparan sulphate and NK1, NK2 and HGF/SF and we discuss their role in HGF/SF-Met signalling.
Introduction
The biological functions of proteoglycans rely on their ability to bind to different molecules including extracellular matrix proteins, enzymes and protease inhibitors. Of increasing interest is their supporting role in the formation of signalling complexes as a result of their capacity to bind to various growth factors. Growth factors activate signalling cascades by triggering tyrosine kinase receptor dimerization and/or further higher order oligomerization. This results in autophosphorylation (probably in trans i.e. between receptors of the dimer) of certain tyrosine residues in the activation loop of the intracellular kinase domain which stimulates kinase activity. The receptor can then proceed to autophosphorylate (either in cis or in trans) further tyrosine residues in the juxtamembrane region, kinase insert and C-terminal regions, creating docking sites for downstream signalling molecules that recognize phosphotyrosines in specific sequence contexts (for a review, see [1] ). In certain instances, this growth factorinduced receptor dimerization is assisted by heparan sulphate (Figure 1 ).
FGFs (fibroblast growth factors) are among the best studied of the heparin-binding growth factors with high-resolution crystal structures available for both the FGF-heparin complex [2] and the FGF-FGFR (FGF receptor)-heparin complex [3, 4] . [Although heparin is not found on the cell surface, unlike heparan sulphate and dermatan sulphate, it has been used extensively especially in structural studies as a substitute for heparan sulphate due to greater availability, structural and chemical similarities and a more homogeneous degree of substitution (Figure 1) ]. In this case, heparin firstly enhances the stability of the binary FGF-FGFR complex by cross-linking the ligand and receptor. Its second role is as a glue between two FGF-FGFR complexes to form the active signalling complex, the stoichiometry of which is disputed [5] . One crystallographic model (FGF1-FGFR2-heparin) shows a single heparin decasaccharide chain bridging both binary complexes, resulting in a 2:2:1 FGF-FGFR-heparin complex. The second model shows two heparin chains, one bound to each binary complex to form two ternary complexes. Additional interactions between the heparin of one FGF-FGFR complex across to the receptor molecule of the other stabilizes the receptor dimer and produces a 2:2:2 complex.
However heparan sulphate may not be as important for all heparin-binding growth factors. Growth factors such as vascular endothelial growth factor and placental growth factor 2 bind heparin but are able to induce receptor dimerization in its absence [6, 7] . In these cases, the function of the low-affinity co-receptor heparin may be to stabilize the receptor-ligand complex and/or increase the concentration of the growth factor at the cell surface, making an interaction with the high-affinity-specific receptor kinetically more favourable. The presence of a heparin-binding domain in selected isoforms may also be a means by which the autocrine and paracrine effects of a growth factor can be modulated by limiting diffusion from the cell surface.
The present paper focuses on the specific role of heparan sulphates in the formation of the active signalling complex between the receptor Met and its ligand HGF/SF (hepatocyte growth factor/scatter factor), discussing the requirement and specificity for heparan sulphate as well as possible functions. 
Met and HGF/SF signalling
The Met tyrosine kinase receptor is a disulphide-linked heterodimer (chains α and β) resulting from cleavage of a single precursor at position 307 in the amino acid chain by the prohormone convertase furin. The extracellular component of Met consists of the full α-chain (residues 25-307) and part of the β-chain (residues 308-932). This extracellular part is divided into six individual protein domains ( Figure 2 ): the sema domain (the entire α-chain and residues 308-515 of the β-chain), the cystine-rich domain (residues 520-561) and four Ig-like domains (residues 562-932). There is then a stretch of amino acids that span the cell membrane (residues 933-955), which is followed by the intracellular kinase domain and C-terminal region (residues 1078-1390).
HGF/SF is a member of the plasminogen-related growth factor family and contains 697 residues in its mature processed form ( Figure 2 ). The α-chain consists of an N-terminal domain (residues 37-123), followed by four Kringle domains: K1-K4 (128-469). The β-chain (495-728) is attached to the α-chain via a disulphide bridge and has a serine protease-like domain fold though it lacks any proteolytic activity [8] .
Activation of Met by HGF/SF results in the phosphorylation of Tyr 1232 and Tyr 1233 in the activation loop of the kinase and subsequently Tyr 1349 and Tyr 1356 in the unstructured region C-terminal to the kinase domain [9] . The latter phosphotyrosines and their surrounding amino acids form a unique bidentate docking site for further downstream signalling molecules such as Gab1 [Grb2 (growth-factor-receptorbound protein 2)-associated binder 1], a scaffolding protein that then recruits further signal-relay molecules such as phosphoinositide 3-kinase, phospholipase C and Crk [9] [10] [11] . Met activation can also trigger the mitogen-activated protein kinase pathway which includes Ras and Raf via the phosphatase Shp2 [SH2 (Src homology 2)-domain-containing tyrosine phosphatase] [12] [13] [14] [15] . These multiple and diverse downstream signalling events give rise to a wide range of biological responses including cell proliferation, motility, angiogenesis, morphogenesis and invasiveness.
The Met-HGF/SF active complex
There are at least two possible ways in which HGF/SF can effect Met dimerization. The first involves two Met receptors binding to two separate and non-equivalent binding sites on one HGF/SF molecule to form a 1:2 ligand-receptor signalling complex. This stoichiometry is seen in the growth hormone-growth hormone receptor complex [16] . In the second model, a 2:2 signalling complex is formed either by association of two binary ligand-receptor complexes or by ligand dimerization. The latter is supported by the X-ray structure of the NK1 homodimer (an isoform of HGF/SF containing only the N and K1 domains) [17, 18] . In this structure, two identical amino acid patches strongly implicated in binding Met (residues Glu 159 , Ser 161 , Glu 195 and Arg 197 ) are present on either side of the dimer (one on each protomer) [19] . Each site would theoretically then be able to engage one receptor molecule, resulting in receptor dimerization. Additionally, size-exclusion chromatography and MALDI-TOF-MS (matrix-assisted laser-desorption ionization-timeof-flight MS) of the Met sema domain in complex with NK1 and heparin support the formation of a 2:2 complex (L.E. Kemp, unpublished work).
Met and HGF/SF associate primarily via their N-terminal regions. Met binds to HGF/SF via its sema domain, which has a β-propeller fold similar to those used by the semaphorins and the integrin α-chain for protein-protein interactions [20, 21] . The N and K1 domains of HGF/SF have been shown to be sufficient to form a high-affinity association with Met although other domains must be involved as NK1 requires heparin to form this interaction, whereas full-length HGF/SF does not [8, 22] . There is also a lower-affinity binding site for the sema domain on the β-chain of HGF-SF (the serine protease-like domain); however, as this contact does not involve heparin, it will not be further discussed [21] .
Requirement for heparan sulphate in the signalling complex
Heparan sulphates are not required for the interaction of Met and full-length HGF/SF in vitro or in vivo. However, in cell assays, the presence of heparin increases the mitogenic potency of HGF/SF and, in vitro, causes the oligomerization of HGF/SF which may facilitate Met receptor dimerization and activation [23] . The situation is more complicated for the naturally occurring HGF/SF isoforms NK1 and NK2 that consist of the N-terminal domain, and the first one and two Kringles of HGF-SF respectively. In vitro, NK1 and NK2 have no effect on cells that do not express heparan sulphate on their cell surface [24] . Addition of exogenous heparin reconstitutes the pleiotropic effects of full-length HGF/SF. In the absence of heparin, neither NK1 nor NK2 binds to Met in vitro with appreciable affinity. However, upon addition of heparin in a 1:1 molar ratio, NK1 and NK2 form homodimers, which are then able to bind to Met (L.E. Kemp, unpublished work). This complex is not thought to be mediated by heparin directly, as is the case with FGF and FGFR, since the twochain mature form of the Met sema domain does not bind heparin in vitro (L.E. Kemp, unpublished work).
Specificity for different glycosaminoglycan structures and chain lengths
HGF/SF binds to heparin, heparan sulphate and dermatan sulphate (Figure 1 ) [25] . The high-affinity heparin-binding site is located in the N-terminal domain of HGF/SF as determined by crystallography and mutagenesis studies [18] . In the crystal structure of the NK1 homodimer in complex with heparin, one heparin molecule is seen bound to each N-terminal domain in an electropositively lined groove. A 14-monosaccharide span of heparin was used to form the NK1-heparin complex used for the crystal structure; however, the entire 14-mer does not bind in the groove and protein-sugar interactions are confined to a stretch of four monosaccharides, approx. 17 Å (1 Å = 0.1 nm) in length. The major contacts form between the 2-O-and 6-O-sulphate groups of the sugar and the backbone nitrogen atoms and side chains of residues Thr 61 , Lys 63 , Arg 73 and Gly 79 . This tetrameric span of heparan sulphate has been shown to be the minimal unit that shows activity in vivo; however, this only applies to a certain subpopulation of tetrameric heparins with the determinant being the position rather than the degree of sulphation [26] . Hexameric heparan sulphate species were shown to be more universally capable of Met kinase activation. The minimal binding species of dermatan sulphate is a hexasaccharide. This can be explained by dermatan's structural dissimilarity from heparan sulphate and it may therefore require a longer span of monosaccharides to fulfil the binding criteria in relation to positions of sulphates.
There is also a secondary lower affinity site present in the K1 domain; however, mutagenesis studies have shown it not to be involved in heparin-dependent dimerization of NK1 [18] . As the N-terminal domain contains the primary heparin-binding site, the HGF/SF truncated isoforms, NK1 and NK2, display essentially the same glycosaminoglycanbinding properties as the full-length ligand [26] .
Possible functions of heparin in Met-HGF/SF complex formation
Heparan sulphate may be used as a repository for HGF/SF, as has been suggested for other heparin-binding growth factors, thus concentrating the ligand at the cell surface and making interaction with Met more energetically favourable [27] . However, it must also play a specific role as exemplified by the absolute requirement of NK1 and NK2 for heparan sulphate to interact with Met in vitro and for their activity in vivo. There are several models for the precise role of heparin in the case of HGF/SF and the discussion that follows focuses initially on NK1 as the structural data so far are limited to this HGF/SF isoform (Figure 3 ).
The first model suggests that NK1 undergoes a conformational change upon interaction with heparin, which enables the ligand to dimerize and bind Met in a stable manner [25] (Figure 3a) . Crystal structures of NK1 (which contains the primary binding site for Met) in the presence and absence of heparin, however, reveal no significant structural differences and it is unclear as to how the primed NK1 monomers would form the dimer as a result of heparin binding.
The second model proposes that heparin stabilizes the ligand dimer. This would suggest that NK1 can form a dimer even in the absence of heparin but that heparin cements the interaction, hence it shifts the equilibrium to the active, dimeric form of the ligand. In the case of HGF/SF domains, heparin is not essential for dimerization presumably because other domains, namely K2-K4 and the serine protease homology domain, may contribute to and stabilize the dimerization interface. However, as yet, only the NK1 fragment of HGF/ SF has been shown to form a relatively strong homodimer (in the presence of heparin) as seen in gel filtration, protein cross-linking and structural studies [17, 18, 24] .
A third model, which incorporates aspects of both the above ones, may explain why heparin/heparan sulphate plays different roles in relation to NK1 and HGF/SF. In the absence of heparin, HGF/SF may require interaction with Met (via NK1 as well as other domains) to expose its dimerization domain. This agrees with results that show HGF/SF to be a monomer in solution [23] and yet appears to form a 2:2 ligand-receptor complex in the presence of truncated forms of the Met ectodomain. Preliminary cryoelectron microscopy images also hint at a conformational change between the unbound and bound forms of HGF/SF (E. Gherardi, unpublished work). Heparan sulphate on the cell surface may negate the need for this primary Met interaction as it may itself cause a conformational change in HGF/ SF, exposing the ligand dimerization domain and providing a ready supply of activated ligand dimers. This has been shown to be the case in vitro where heparin causes the oligomerizations of HGF/SF and may explain why heparin enhances HGF/SF signalling but is not an absolute requirement.
Extending this paradigm to NK1, the truncated form of the ligand would be unable to interact with Met due to the absence of the other domains, which make up the full-length ligand and which may position the N and K1 domains in such a way as to promote Met association and subsequent ligand dimerization (Figure 3 ). The N and K domains are joined by a flexible linker and in the absence of heparin may fail to present their receptor-binding surface in concert. On addition of heparin, NK1 forms a homodimer in which the N and K1 domains are rigidified by inter-protomeric contacts and may then be able to interact with Met using both domains. Mutagenesis studies support this model with two mutationsensitive amino acid clusters pinpointed, one on the N and the other on the K1 domain [19, 28] , which in the crystal structure of the NK1 dimer are located on the same face of each protomer [17, 18, 29] . Thus, in the case of NK1, heparin may not only promote dimerization of the ligand but, as a consequence of this dimerization, position the N and K1 receptor binding faces so as to promote Met association.
Concluding remarks
The role of heparin/heparan sulphate in forming the active Met-HGF/SF complex is still yet to be clearly defined despite the considerable amount of work carried out. It is apparent that heparan sulphate plays an important physiological role in this signalling system which is dependent on both the structure and number of monosaccharides present in the heparin chain. Heparan sulphate is required to a varying degree by HGF/SF and its isoforms to achieve Met dimerization and trigger various signalling pathways. The function of heparan sulphate may include stabilization of the dimeric ligand, as an instigator of conformational change, as a repository of the ligand or a combination of these, and further studies are clearly required to ascertain the function of heparan sulphate co-receptor in the HGF/SF-Met signalling system. This work was supported by MRC Programme Grant G9704528.
